DSGN · Design Therapeutics, Inc.
$12.00
+0.13 (+1.10%)
At close · Jul 29
Market Cap
$741.36M
Shares
62.46M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$0
FY2025
Net Income
-$69.79M
-40.7%
FY2025
Operating Margin
-3685.84%
FY2020
Diluted EPS
-$1.22
-38.6%
FY2025
Operating Cash Flow
-$54.36M
-26.1%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|---|
| — | $0 | $0 | — | — | — | $226K | |
| $58.13M | $59.13M | $44.35M | $57.06M | $48.61M | $24.78M | $6.06M | |
| $20.62M | $20.34M | $18.03M | $21.13M | $18.98M | $11.05M | $2.5M | |
| $78.76M | $79.47M | $62.38M | $78.19M | $67.59M | $35.83M | $8.56M | |
| -$78.76M | -$79.47M | -$62.38M | -$78.19M | -$67.59M | -$35.83M | -$8.33M | |
| — | — | — | — | — | — | -3685.84% | |
| $9.04M | $9.68M | $12.8M | $11.33M | — | — | — | |
| $13.03M | — | — | $11.33M | $4.29M | $298K | $50K | |
| — | $0 | $0 | — | — | — | — | |
| -$69.71M | -$69.79M | -$49.59M | -$66.86M | -$63.31M | -$35.53M | -$8.28M | |
| — | — | — | — | — | — | -3663.72% | |
| -$70.43M | -$69.86M | -$49.18M | -$63.44M | -$66.42M | -$35.93M | -$8.12M | |
| USD/shares | — | -$1.22 | -$0.88 | -$1.19 | -$1.14 | -$0.77 | — |
| USD/shares | — | -$1.22 | -$0.88 | -$1.19 | -$1.14 | -$0.77 | — |
| shares | — | 57.33M | 56.59M | 55.98M | 55.71M | 45.94M | 15.8M |
| shares | — | 57.33M | 56.59M | 55.98M | 55.71M | 45.94M | 15.8M |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 4.65×
EV/EBIT
—
Peer median 24.46×
P/E (TTM)
—
Peer median 10.86×
Peer medians compare against the 301 similar-size Biotechnology companies (of 522 listed).
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Product & Service (USD)
| Component | FY2020 |
|---|---|
| Grant | $200,000 |
Key facts
CIK
1807120
CUSIP
25056L103
13F (30d)
18 filings
18 filers
Visit website
Investor relations